Evidence map›Paper›PMID 35496954›Full record

ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2022

Clinico-Epidemiological Profile, Prognostic Factors and Treatment Outcome of Refractory Hodgkin Lymphoma.

Yosr Zenzri, Amina Mokrani, Feryel Letaief, Mouna Ayadi, Amel Mezlini

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yosr ZenzriMedical Oncology Department, Salah Azaiz Institute, boulevard du 9-Avril 1938, 1006 Tunis, Tunisia.ORCID 0000-0002-0520-8594
Amina MokraniMedical Oncology Department, Salah Azaiz Institute, boulevard du 9-Avril 1938, 1006 Tunis, Tunisia.
Feryel LetaiefMedical Oncology Department, Salah Azaiz Institute, boulevard du 9-Avril 1938, 1006 Tunis, Tunisia.
Mouna AyadiMedical Oncology Department, Salah Azaiz Institute, boulevard du 9-Avril 1938, 1006 Tunis, Tunisia.
Amel MezliniMedical Oncology Department, Salah Azaiz Institute, boulevard du 9-Avril 1938, 1006 Tunis, Tunisia.
Institut Salah-Azaïz · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 5-10% of patients with Hodgkin lymphoma are refractory to initial treatment. The aim of our study was to assess the clinico-epidemiological profile, prognostic factors and treatment outcome. A retrospective study was conducted over a period of 12 years between June 2006 and January 2018 at the oncology department of Salah Azaïz Institute. Thirty-one patients were included. The median age was 27 years with a female predominance (sex ratio = 0.93).The majority had an advanced stage (61%). IGEV regimen was the most commonly used salvage chemotherapy (n = 14). Age above 30 years was predictive of treatment failure after salvage therapy ( Supplementary Information: The online version contains supplementary material available at 10.1007/s12288-021-01463-4.

Indexed as

Autologous stem cell transplantChemotherapyHodgkin lymphomaPrognosisSurvival

Identifiers

PMID35496954
PMCPMC9001764
OpenAlexW3191340488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.